Novel CF3O-heterocyclic systems for prostate cancer chemotherapy

ORGN 735

Mykhailo V. Vovk, mvovk@ioch.kiev.ua1, Volodymyr Sukach1, Nina Melínichenko1, and Andrei A. Gakh, gakhaa@ornl.gov2. (1) Institute of Organic Chemistry, National Academy of Science of Ukraine, Murmansíka 5, 02094, Kyiv, Ukraine, (2) Oak Ridge National Laboratory, Oak Ridge, TN 37831-6242
The presence of trifluoromethoxy group in heterocyclic compounds can enhance specific pharmacological properties of the molecules. We have developed several efficient methods of synthesis of new heterocyclic compounds bearing trifluoromethoxy group from commercially available 4-trifluoromethoxyaniline: 1-(4-trifluoromethoxyphenyl)pyrroles,5-trifluoromethoxyindoles, 5(6)-trifluoromethoxybenzimidazoles,3-(4-trifluoromethoxyphenyl)imidazoles, 5-(4-trifluoromethoxyphenyl)amino-1,3,4-thiadiazoles, 4-(4-trifluoromethoxyphenyl)-1,2,4-triazoles and 1-(4-trifluoromethoxyphenyl)-5Н-tetrazoles. Some of these compounds demonstrated anti-cancer activity and could be considered for prostate cancer chemotherapy. This research was supported by the Global IPP program through the Science and Technology Center in Ukraine (STCU). Oak Ridge National Laboratory is managed by UT-Battelle, LLC, under contract DE-AC05-00OR22725 for the U.S. Department of Energy. This paper is a contribution from the Discovery Chemistry Project.